ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Crohn’s disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in progressive bowel damage and disability.1 CD can affect individuals of any age, from children to the elderly,2,3 and may cause significant morbidity and impact on quality of life [QoL]. The precise aetiology of CD remains unknown and a curative therapy is not yet available. Contemporary therapy therefore is focused on control of inflammation, using medications along with timely surgical interventions to alleviate the symptoms of bowel damage. The European Crohn’s and Colitis Organisation [ECCO] produces several guidelines aimed at providing evidence-based guidance on critical aspects of IBD care. In 2020, ECCO published new guidelines on the management of CD in two manuscripts focused on the medical and surgical management of disease.4,5 For the 2020 CD guidelines, ECCO adopted the Grading of Recommendations Assessment, Development, and Evaluation [GRADE] approach, a systematic process for developing guidelines that addresses how to frame the health care questions, summarise the evidence, formulate the recommendations, and grade their strength and quality of associated evidence.6 The present manuscript represents an update to the 2020 guidelines and is focused specifically on medical management of CD, and a companion manuscript developed as part of the same process addresses optimal surgical management.5 We take a drug-by-drug approach to review the evidence for various medical and dietary strategies used in the management of CD. For this iteration of the guidelines, we have introduced several new, clinically relevant questions as chosen by members of the guidelines group, a systematic approach to reviewing and updating previous topics to incorporate any new evidence, and a reappraisal of all evidence in the context of contemporary practice. We have also introduced several ‘practice points’ to summarise evidence, and expert recommendations in certain key areas of practice where the evidence base is limited but where clinicians and patients need to make decisions nonetheless. Here, where application of the GRADE methodology might be impractical, we have used an approach based on systematic literature review, expert discussion, and voting to form consensus recommendations outside the formal GRADE process. It is important to remember that achieving optimal outcomes in CD relies not just on knowledge of the appropriate use of current medical and surgical therapies but also on careful attention to wider aspects of management, including early diagnosis, prompt initial management,7 close monitoring of treatment response, and psychological and dietary support.8 The development of these guidelines followed the GRADE workflow, as adopted in previous ECCO guidelines.9 A panel of 46 experts were selected from an open call according to criteria based on IBD expertise, scientific background, knowledge of GRADE methodology, and prior contribution to ECCO projects. Additionally, six patients with CD selected by the European Federation of Crohn’s and Colitis Associations [EFFCA] were invited to participate in discussions. The group was supported in their work by a team of professional methodologists and librarians. The panellists first agreed on a list of questions using the Population, Intervention, Comparator, Outcomes [PICO] format. PICO questions addressed as part of the 2020 ECCO CD guidelines were reviewed and considered for retention with regards to ongoing relevance, and new PICO questions were formulated, discussed, and added to the list. The relevant outcomes for all PICO questions were graded according to importance using a Delphi consensus process. Note that for PICO questions retained from 2020, the importance of the outcomes was nonetheless revised according to the results of this new consensus. The professional librarians next performed a comprehensive literature search on EMBASE, PubMed/Medline, and Cochrane Central databases, using specific search strings developed for each PICO question [Supplementary files available as Supplementary data at ECCO-JCC online]. For PICO questions retained from the 2020 guidelines, the same search string was used as during the prior literature search, and the start date of database queries set to the same as the end search date for the previous guidelines 1 April 2018. For all new PICO questions, the search start date was unlimited. Two independent consensus group members assessed the relevance of each abstract to the PICO and included or excluded all the relevant papers for the final data extraction and analysis. Subsequently, group members systematically reviewed and summarised the evidence on every outcome voted as ‘important’ or ‘critical’, to compile a Summary of Findings [SoF] table for each question, or updated the prior SoF tables from 2020 [including revision according to any changes to outcomes deemed critical or important]. We adopted a standard hierarchical approach, searching fo
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
Self-citationVedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
Self-citationNational Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Atkins, D., Eccles, M., Flottorp, S., Guyatt, G. H., Henry, D., Hill, S., Liberati, A., O'Connell, D., Oxman, A. D., Phillips, B., et al. (2004) · BMC Health Services Research · doi:10.1186/1472-6963-4-38 · Cited by 1,235
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,134
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
Adamina, M., Bonovas, S., Raine, T., Spinelli, A., Warusavitarne, J., Armuzzi, A., Bachmann, O., Bager, P., Biancone, L., Bokemeyer, B., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz187 · Cited by 1,106
Self-citationRutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Treatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
Malchow, H., Ewe, K., Brandes, J. W., Goebell, H., Ehms, H., Sommer, H., & Jesdinsky, H. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90409-8 · Cited by 933
Colombel, J.-F., Panaccione, R., Bossuyt, P., Lukas, M., Baert, F., Vaňásek, T., Danalioglu, A., Novacek, G., Armuzzi, A., Hébuterne, X., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32641-7 · Cited by 921
Methotrexate for the Treatment of Crohn's Disease
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320503 · Cited by 911
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 836
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Price, S., Langholff, W., Londhe, A., & Sandborn, W. J. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.218 · Cited by 791
Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.014 · Cited by 753
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
van Rheenen, P. F., Aloi, M., Assa, A., Bronsky, J., Escher, J. C., Fagerberg, U. L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa161 · Cited by 729
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422202 · Cited by 727
Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Kennedy, N. A., Heap, G. A., Green, H. D., Hamilton, B., Bewshea, C., Walker, G. J., Thomas, A., Nice, R., Perry, M. H., Bouri, S., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30012-3 · Cited by 691
Relling, M. V., Schwab, M., Whirl‐Carrillo, M., Suarez‐Kurtz, G., Pui, C., Stein, C. M., Moyer, A. M., Evans, W. E., Klein, T. E., Antillon‐Klussmann, F. G., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1304 · Cited by 682
Kirchgesner, J., Lemaitre, M., Carrat, F., Zureik, M., Carbonnel, F., & Dray-Spira, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.012 · Cited by 609
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Rutgeerts, P., Van Assche, G., Sandborn, W. J., Wolf, D. C., Geboes, K., Colombel, J., Reinisch, W., Kumar, A., Lazar, A., Camez, A., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.035 · Cited by 580
A controlled double blind study of azathioprine in the management of Crohn's disease.
Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., & Goodman, R. (1995) · Gut · doi:10.1136/gut.37.5.674 · Cited by 567
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
Rutgeerts, P., Diamond, R. H., Bala, M., Olson, A., Lichtenstein, G. R., Bao, W., Patel, K., Wolf, D. C., Safdi, M., Colombel, J. F., et al. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2005.08.011 · Cited by 548
Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J., & Sands, B. E. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.01.004 · Cited by 511
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
Loftus, E. V., Panés, J., Lacerda, A. P., Peyrin-Biroulet, L., D’Haens, G., Panaccione, R., Reinisch, W., Louis, E., Chen, M., Nakase, H., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212728 · Cited by 483
Khanna, R., Bressler, B., Levesque, B. G., Zou, G., Stitt, L. W., Greenberg, G. R., Panaccione, R., Bitton, A., Paré, P., Vermeire, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00068-9 · Cited by 460
Steenholdt, C., Brynskov, J., Thomsen, O. Ø., Munck, L. K., Fallingborg, J., Christensen, L. A., Pedersen, G., Kjeldsen, J., Jacobsen, B. A., Oxholm, A. S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305279 · Cited by 460
D'Haens, G., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00467-6 · Cited by 433
Sazonovs, A., Kennedy, N. A., Moutsianas, L., Heap, G. A., Rice, D. L., Reppell, M., Bewshea, C. M., Chanchlani, N., Walker, G. J., Perry, M. H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.041 · Cited by 423
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub3 · Cited by 402
Baeten, D., Østergaard, M., Wei, J. C.-C., Sieper, J., Järvinen, P., Tam, L.-S., Salvarani, C., Kim, T.-H., Solinger, A., Datsenko, Y., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213328 · Cited by 390
Cox, S. R., Lindsay, J. O., Fromentin, S., Stagg, A. J., McCarthy, N. E., Galleron, N., Ibraim, S. B., Roume, H., Levenez, F., Pons, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.024 · Cited by 382
ESPEN guideline on Clinical Nutrition in inflammatory bowel disease
Bischoff, S. C., Bager, P., Escher, J., Forbes, A., Hébuterne, X., Hvas, C. L., Joly, F., Klek, S., Krznaric, Z., Ockenga, J., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2022.12.004 · Cited by 367
Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
Singleton, J. W., Hanauer, S. B., Gitnick, G. L., Peppercorn, M. A., Robinson, M. G., Wruble, L. D., & Krawitt, E. L. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90337-c · Cited by 357
de Jong, M. J., van der Meulen-de Jong, A. E., Romberg-Camps, M. J., Becx, M. C., Maljaars, J. P., Cilissen, M., van Bodegraven, A. A., Mahmmod, N., Markus, T., Hameeteman, W. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31327-2 · Cited by 350
Ferrante, M., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J.-F., Danese, S., Dubinsky, M., Feagan, B. G., Hisamatsu, T., Lim, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00466-4 · Cited by 345
Feagan, B. G., McDonald, J. W. D., Panaccione, R., Enns, R. A., Bernstein, C. N., Ponich, T. P., Bourdages, R., MacIntosh, D. G., Dallaire, C., Cohen, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.024 · Cited by 331
A Comparison of Budesonide and Mesalamine for Active Crohn's Disease
Thomsen, O. Ø., Cortot, A., Jewell, D., Wright, J. P., Winter, T., Veloso, F. T., Vatn, M., Persson, T., & Pettersson, E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390603 · Cited by 327
Lewis, J. D., Sandler, R. S., Brotherton, C., Brensinger, C., Li, H., Kappelman, M. D., Daniel, S. G., Bittinger, K., Albenberg, L., Valentine, J. F., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.047 · Cited by 320
ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjad108 · Cited by 318
Self-citationSvolos, V., Hansen, R., Nichols, B., Quince, C., Ijaz, U. Z., Papadopoulou, R. T., Edwards, C. A., Watson, D., Alghamdi, A., Brejnrod, A., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.002 · Cited by 317
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Gordon, H., Biancone, L., Fiorino, G., Katsanos, K. H., Kopylov, U., Al Sulais, E., Axelrad, J. E., Balendran, K., Burisch, J., de Ridder, L., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac187 · Cited by 317
Self-citationCONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Willoughby, J. M. T., Beckett, J., Kumar, P., & Dawson, A. M. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90268-6 · Cited by 314
Noor, N. M., Lee, J. C., Bond, S., Dowling, F., Brezina, B., Patel, K. V., Ahmad, T., Banim, P. J., Berrill, J. W., Cooney, R., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00034-7 · Cited by 310
Self-citationIncreased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
Long, M. D., Herfarth, H. H., Pipkin, C. A., Porter, C. Q., Sandler, R. S., & Kappelman, M. D. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.11.024 · Cited by 306
D’Haens, G., Vermeire, S., Lambrecht, G., Baert, F., Bossuyt, P., Pariente, B., Buisson, A., Bouhnik, Y., Filippi, J., vander Woude, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.004 · Cited by 305
Enteral nutritional therapy for induction of remission in Crohn's disease
Narula, N., Dhillon, A., Zhang, D., Sherlock, M. E., Tondeur, M., & Zachos, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000542.pub3 · Cited by 301
Singh, S., Murad, M. H., Fumery, M., Sedano, R., Jairath, V., Panaccione, R., Sandborn, W. J., & Ma, C. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00312-5 · Cited by 298
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
Akobeng, A. K., Zhang, D., Gordon, M., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003715.pub3 · Cited by 289
Greenberg, G., Feagan, B., Martin, F., Sutherland, L., Thomson, A., Williams, C., Nilsson, L., & Persson, T. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8536887 · Cited by 288
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Colombel, J.-F., D’haens, G., Lee, W.-J., Petersson, J., & Panaccione, R. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz131 · Cited by 283
European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Torres, J., Chaparro, M., Julsgaard, M., Katsanos, K., Zelinkova, Z., Agrawal, M., Ardizzone, S., Campmans-Kuijpers, M., Dragoni, G., Ferrante, M., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac115 · Cited by 281
Self-citationNational Cooperative Crohn's Disease Study: Adverse reactions to study drugs
Singleton, J. W., Law, D. H., Kelley, M. L., Mekhjian, H. S., & Sturdevant, R. A. L. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90386-x · Cited by 263
Budesonide for induction of remission in Crohn's disease
Rezaie, A., Kuenzig, M. E., Benchimol, E. I., Griffiths, A. M., Otley, A. R., Steinhart, A. H., Kaplan, G. G., & Seow, C. H. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000296.pub4 · Cited by 260
Hanauer, S. B., & Strömberg, U. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00122-3 · Cited by 246
Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease
Ungaro, R. C., Yzet, C., Bossuyt, P., Baert, F. J., Vanasek, T., D’Haens, G. R., Joustra, V. W., Panaccione, R., Novacek, G., Reinisch, W., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.039 · Cited by 241
Aminosalicylates for induction of remission or response in Crohn's disease
Lim, W.-C., Wang, Y., MacDonald, J. K., & Hanauer, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008870.pub2 · Cited by 239
Matsumoto, T., Motoya, S., Watanabe, K., Hisamatsu, T., Nakase, H., Yoshimura, N., Ishida, T., Kato, S., Nakagawa, T., Esaki, M., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw152 · Cited by 238
Schreiber, S., Ben-Horin, S., Leszczyszyn, J., Dudkowiak, R., Lahat, A., Gawdis-Wojnarska, B., Pukitis, A., Horynski, M., Farkas, K., Kierkus, J., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.068 · Cited by 236
An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report
Olendzki, B. C., Silverstein, T. D., Persuitte, G. M., Ma, Y., Baldwin, K. R., & Cave, D. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-5 · Cited by 235
Adverse effects of biologics: a network meta‐analysis and Cochrane overview
(2011) · Prescriber · doi:10.1002/psb.747 · Cited by 234
Yanai, H., Levine, A., Hirsch, A., Boneh, R. S., Kopylov, U., Eran, H. B., Cohen, N. A., Ron, Y., Goren, I., Leibovitzh, H., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00299-5 · Cited by 226
Self-citationEfficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis
Ford, A. C., Kane, S. V., Khan, K. J., Achkar, J.-P., Talley, N. J., Marshall, J. K., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.71 · Cited by 223
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
Ewe, K., Press, A. G., Singe, C. C., Stufler, M., Ueberschaer, B., Hommel, G., & Büschenfelde, K.-H. M. Z. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90709-l · Cited by 217
Danese, S., Sandborn, W. J., Colombel, J.-F., Vermeire, S., Glover, S. C., Rimola, J., Siegelman, J., Jones, S., Bornstein, J. D., & Feagan, B. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.038 · Cited by 216
Hanauer, S. B., Sandborn, W. J., Feagan, B. G., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Adedokun, O. J., Sands, B. E., Rutgeerts, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz110 · Cited by 213
IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
Jones, G.-R., Lyons, M., Plevris, N., Jenkinson, P. W., Bisset, C., Burgess, C., Din, S., Fulforth, J., Henderson, P., Ho, G.-T., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318936 · Cited by 206
Sands, B. E., Kozarek, R., Spainhour, J., Barish, C. F., Becker, S., Goldberg, L., Katz, S., Goldblum, R., Harrigan, R., Hilton, D., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20014 · Cited by 206
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
Sandborn, W. J., D’Haens, G. R., Reinisch, W., Panés, J., Chan, D., Gonzalez, S., Weisel, K., Germinaro, M., Frustaci, M. E., Yang, Z., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.01.047 · Cited by 206
Oren, R., Moshkowitz, M., Odes, S., Becker, S., Keter, D., Pomeranz, I. S., Shirin, H., Shirin, C., Reisfeld, I., Broide, E., et al. (1997) · PubMed · Cited by 200
Ahmed, W., Galati, J., Kumar, A., Christos, P. J., Longman, R., Lukin, D. J., Scherl, E., & Battat, R. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.034 · Cited by 199
Self-citationColombel, J.-F., Adedokun, O. J., Gasink, C., Gao, L.-L., Cornillie, F. J., D'Haens, G. R., Rutgeerts, P. J., Reinisch, W., Sandborn, W. J., & Hanauer, S. B. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.09.033 · Cited by 189
CONTROLLED TRIAL OF AZATHIOPRINE IN CROHN'S DISEASE
Rhodes, J., Beck, P., Bainton, D., & Campbell, H. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90598-8 · Cited by 184
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
Rutgeerts, P., Gasink, C., Chan, D., Lang, Y., Pollack, P., Colombel, J.-F., Wolf, D. C., Jacobstein, D., Johanns, J., Szapary, P., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.035 · Cited by 184
Barberio, B., Gracie, D. J., Black, C. J., & Ford, A. C. (2023) · Gut · doi:10.1136/gutjnl-2022-328052 · Cited by 183
Methotrexate for maintenance of remission in Crohn's disease
Patel, V., Wang, Y., MacDonald, J. K., McDonald, J. W., & Chande, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006884.pub3 · Cited by 180
Vermeire, S., D’Haens, G., Baert, F., Danese, S., Kobayashi, T., Loftus, E. V., Bhatia, S., Agboton, C., Rosario, M., Chen, C., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab133 · Cited by 178
Self-citationCertolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
Sandborn, W. J., Schreiber, S., Feagan, B. G., Rutgeerts, P., Younes, Z. H., Bloomfield, R., Coteur, G., Guzman, J. P., & D'Haens, G. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.04.031 · Cited by 175
Papamichael, K., Afif, W., Drobne, D., Dubinsky, M. C., Ferrante, M., Irving, P. M., Kamperidis, N., Kobayashi, T., Kotze, P. G., Lambert, J., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00223-5 · Cited by 171
Self-citationSyversen, S. W., Jørgensen, K. K., Goll, G. L., Brun, M. K., Sandanger, Ø., Bjørlykke, K. H., Sexton, J., Olsen, I. C., Gehin, J. E., Warren, D. J., et al. (2021) · JAMA · doi:10.1001/jama.2021.21316 · Cited by 167
Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel Disease
Singh, H., Nugent, Z., Demers, A. A., & Bernstein, C. N. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.039 · Cited by 164
Kapizioni, C., Desoki, R., Lam, D., Balendran, K., Sulais, E. A., Subramanian, S., Rimmer, J. E., Negro, J. D. L. R., Pavey, H., Pele, L., et al. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad203 · Cited by 162
Self-citationBreaking through the therapeutic ceiling: what will it take?
Raine, T., & Danese, S. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.09.078 · Cited by 160
Self-citationTreatment of Crohn's Disease with Azathioprine: A Controlled Evaluation
Klein, M., Binder, H. J., Mitchell, M., Aaronson, R., & Spiro, H. (1974) · Gastroenterology · doi:10.1016/s0016-5085(74)80166-6 · Cited by 158
Dietary management of adults with IBD — the emerging role of dietary therapy
Fitzpatrick, J. A., Melton, S. L., Yao, C. K., Gibson, P. R., & Halmos, E. P. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00619-5 · Cited by 156
Roblin, X., Williet, N., Boschetti, G., Phelip, J., Tedesco, É. D., Berger, A.-E., Vedrines, P., Duru, G., Peyrin‐Biroulet, L., Nancey, S., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319758 · Cited by 153
Kristensen, L. E., Keiserman, M. W., Papp, K. A., McCasland, L., White, D., Lu, W., Wang, Z., Soliman, A. M., Eldred, A., Barcomb, L. M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221019 · Cited by 152
Yang, E., Panaccione, N., Whitmire, N., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15719 · Cited by 147
Tremaine, W. J., Schroeder, K. W., Harrison, J. M., & Zinsmeister, A. R. (1994) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199412000-00003 · Cited by 146
Fine, S., Papamichael, K., & Cheifetz, A. S. (2019) · PubMed · Cited by 141
Self-citationBen‐Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J., Kobayashi, T., Hibi∥, T., Chowers, Y., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.10.037 · Cited by 137
Self-citationDanese, S., Vermeire, S., D’Haens, G., Panés, J., Dignass, A., Magro, F., Nazar, M., Bars, M. L., Lahaye, M., Ni, L., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00474-x · Cited by 133
Self-citationRasmussen, S. N., Lauritsen, K., Tage‐Jensen, U., Nielsen, O. H., Bytzer, P., Jacobsen, O., Ladefoged, K., VILIEN, M., Binder, V., Rask-Madsen, J., et al. (1987) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528708991929 · Cited by 131
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Chande, N., Townsend, C., Parker, C. E., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub5 · Cited by 122
Tremaine, W. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04191-6 · Cited by 119
Perioperative Dietary Therapy in Inflammatory Bowel Disease
Adamina, M., Gerasimidis, K., Boneh, R. S., Zmora, O., van Overstraeten, A. D. B., Campmans-Kuijpers, M. J. E., Ellul, P., Katsanos, K. H., Kotze, P. G., Noor, N. M., et al. (2019) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjz160 · Cited by 115
Self-citationChupin, A., Perduca, V., Meyer, A., Bellanger, C., Carbonnel, F., & Dong, C. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16050 · Cited by 114
Panaccione, R., Colombel, J. F., Sandborn, W. J., Rutgeerts, P., D’Haens, G., Robinson, A. M., Chao, J., Mulani, P. M., & Pollack, P. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04304.x · Cited by 113
Lofland, J. H., Johnson, P. T., Ingham, M., Rosemas, S. C., White, J. C., & Ellis, L. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s133222 · Cited by 105
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)
Colombel, J., Ungaro, R. C., Sands, B. E., Siegel, C. A., Wolf, D. C., Valentine, J. F., Feagan, B. G., Neustifter, B., Kadali, H., Nazarey, P., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.09.010 · Cited by 105
Kopylov, U., Vutcovici, M., Kezouh, A., Seidman, E. G., Bitton, A., & Afif, W. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000457 · Cited by 104
Self-citationReinisch, W., Panés, J., Lémann, M., Schreiber, S., Feagan, B. G., Schmidt, S. L., Sturniolo, G. C., Mikhailova, T. L., Alexeeva, O., Sanna, L., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02024.x · Cited by 102
Limketkai, B. N., Brewer, G. G., Parian, A. M., Noorian, S., Krishna, M., Shah, N. D., White, J., & Mullin, G. E. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.11.026 · Cited by 99
Efficacy of exclusive enteral nutrition in complicated Crohn’s disease
Yang, Q., Gao, X., Chen, H., Li, M., Wu, X., Zhi, M., Lan, P., & Hu, P. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1335770 · Cited by 98
The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease
Dorrington, A., Selinger, C. P., Parkes, G. C., Smith, M. A., Pollok, R., & Raine, T. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa053 · Cited by 97
Self-citationAlayo, Q. A., Fenster, M., Altayar, O., Glassner, K. L., Llano, E. M., Clark‐Snustad, K., Patel, A. A., Kwapisz, L., Yarur, A. J., Cohen, B. L., et al. (2021) · Crohn s & Colitis 360 · doi:10.1093/crocol/otac002 · Cited by 97
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease
MacDonald, J. K., Nguyen, T. M., Khanna, R., & Timmer, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007572.pub3 · Cited by 96
Kopylov, U., Al-Taweel, T., Yaghoobi, M., Nauche, B., Bitton, A., Lakatos, P. L., Ben‐Horin, S., Afif, W., & Seidman, E. G. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.07.003 · Cited by 94
Self-citationNguyen, D. L., Palmer, L. B., Nguyen, E. T., McClave, S. A., Martindale, R. G., & Bechtold, M. L. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15578607 · Cited by 94
Tromm, A., Bunganič, I., Tomsová, E., Tulassay, Z., Lukáš, M., Kykal, J., Bátovský, M., Fixa, B., Gabalec, L., Safadi, R., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.11.004 · Cited by 93
D’Haens, G., Sandborn, W. J., Loftus, E. V., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.01.044 · Cited by 89
CYP3A4 and CYP3A5 Genotyping Recommendations
Pratt, V. M., Cavallari, L. H., Fulmer, M. L., Gaedigk, A., Hachad, H., Ji, Y., Kalman, L. V., Ly, R. C., Moyer, A. M., Scott, S. A., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.06.008 · Cited by 88
‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review
Fiorino, G., Allocca, M., Chaparro, M., Coenen, S., Fidalgo, C. A., Younge, L., & Gisbert, J. P. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy140 · Cited by 86
Self-citationCoward, S., Kuenzig, M. E., Hazlewood, G. S., Clement, F. M., McBrien, K., Holmes, R. S., Panaccione, R., Ghosh, S. K., Seow, C. H., Rezaie, A. R., et al. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001023 · Cited by 85
Szczubełek, M., Pomorska, K., Korólczyk-Kowalczyk, M., Lewandowski, K., Kaniewska, M. A., & Rydzewska, G. M. (2021) · Nutrients · doi:10.3390/nu13114112 · Cited by 84
Stournaras, E., Qian, W., Pappas, A., Hong, Y. Y., Shawky, R., UK IBD BioResource Investigators, Raine, T., & Parkes, M. (2020) · Gut · doi:10.1136/gutjnl-2019-320185 · Cited by 81
Self-citationMoja, L., Danese, S., Fiorino, G., Giovane, C. D., & Bonovas, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13190 · Cited by 80
Self-citationSethi, S., Dias, S., Kumar, A., Blackwell, J., Brookes, M., & Segal, J. P. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17313 · Cited by 80
Nguyen, N. H., Solitano, V., Vuyyuru, S. K., MacDonald, J. K., Syversen, S. W., Jørgensen, K. K., Crowley, E., Ma, C., Jairath, V., & Singh, S. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.052 · Cited by 74
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease
Li, K., Friedman, J. R., Chan, D., Pollack, P., Yang, F., Jacobstein, D., Brodmerkel, C. M., Gasink, C., Feagan, B. G., Sandborn, W. J., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.037 · Cited by 71
Targownik, L. E., Benchimol, E. I., Bernstein, C. N., Singh, H., Tennakoon, A., Zubieta, A. A., Coward, S., Jones, J., Kaplan, G. G., Kuenzig, M. E., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa050 · Cited by 71
Traditional corticosteroids for induction of remission in Crohn's disease
Benchimol, E. I., Seow, C., Steinhart, A. H., & Griffiths, A. M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006792 · Cited by 69
ECCO Topical Review: Refractory Inflammatory Bowel Disease
Raine, T., Verstockt, B., Kopylov, U., Κarmiris, K., Goldberg, R., Atreya, R. N., Burisch, J. M., Burke, J. P., Ellul, P., Hedin, C. R. H., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab112 · Cited by 68
Self-citationComparative Incidence of Inflammatory Bowel Disease in Different Age Groups in the United States
Keyashian, K., Dehghan, M. S., Sceats, L. A., Kin, C., Limketkai, B. N., & Park, K. T. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz092 · Cited by 67
Selinger, C. P., Parkes, G. C., Bassi, A., Limdi, J. K., Ludlow, H., Patel, P., Smith, M. A., Saluke, S., Ndlovu, Z., George, B., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15497 · Cited by 66
Self-citationWatanabe, K., Motoya, S., Ogata, H., Kanai∥, T., Matsui, T., Suzuki, Y., Shikamura, M., Sugiura, K., Oda, K., Hori, T., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01647-w · Cited by 64
Coenen, S., Weyts, E., Vermeire, S., Ferrante, M., Noman, M., Ballet, V., Vanhaecht, K., & Assche, G. V. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000839 · Cited by 62
Peter, I., Maldonado‐Contreras, A., Eisele, C. D., Frisard, C., Simpson, S., Nair, N. K., Rendon, A. P., Hawkins, K. A., Cawley, C., Debebe, A., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100573 · Cited by 59
Self-citationSuzuki, Y., Motoya, S., Takazoe, M., Kosaka, T., Date, M., Nii, M., & Hibi∥, T. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.06.006 · Cited by 55
Carlsen, K., Houen, G., Jakobsen, C., Kallemose, T., Pærregaard, A., Riis, L. B., Munkholm, P., & Wewer, V. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001170 · Cited by 51
Chen, B., Gao, X., Zhong, J., Ren, J., Zhu, X., Liu, Z., Wu, K., Kalabic, J., Yu, Z., Huang, B., et al. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820938960 · Cited by 50
Watanabe, K., Matsumoto, T., Hisamatsu, T., Nakase, H., Motoya, S., Yoshimura, N., Ishida, T., Kato, S., Nakagawa, T., Esaki, M., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.10.036 · Cited by 47
Márquez-Megías, S., Nalda‐Molina, R., Sanz‐Valero, J., Más‐Serrano, P., Díaz-González, M., Candela-Boix, M. R., & Ramón-López, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051009 · Cited by 46
Oh, E. H., Oh, K., Han, M., Seo, H., Chang, K., Lee, S.-H., Kim, G., Song, E. M., Seo, M., Lee, H., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177479 · Cited by 45
Kuenzig, M. E., Rezaie, A. R., Kaplan, G. G., Otley, A. R., Steinhart, A. H., Griffiths, A. M., Benchimol, E. I., & Seow, C. H. (2018) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy018 · Cited by 43
Integrated care models: Optimizing adult ambulatory care in inflammatory bowel disease
Schoenfeld, R., Nguyen, G. C., & Bernstein, C. N. (2020) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwy060 · Cited by 42
Macaluso, F. S., Ventimiglia, M., & Orlando, A. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad043 · Cited by 40
D’Haens, G., Reinisch, W., Schreiber, S., Cummings, F. J. R., Irving, P. M., Ye, B. D., Kim, D., Yoon, S.-W., & Ben‐Horin, S. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01252-z · Cited by 40
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
Papamichael, K., & Cheifetz, A. S. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000713 · Cited by 35
Self-citationSands, B. E., Han, C., Gasink, C., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy055 · Cited by 33
Yang, H., Feng, R., Li, T., Xu, S., Hao, X., Qiu, Y., & Chen, M. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.06.006 · Cited by 33
Isakov, N. F., Cohen, N. A., Bromberg, A., Elbert, G., Anbar, R., Ron, Y., Hirsch, A., Thurm, T., & Maharshak, N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165428 · Cited by 29
Yokoyama, T., Ohta, A., Motoya, S., Takazoe, M., Yajima, T., Date, M., Nii, M., Nagy, P., Suzuki, Y., & Hibi∥, T. (2017) · Inflammatory Intestinal Diseases · doi:10.1159/000484047 · Cited by 23
Alvestad, L., Jelsness‐Jørgensen, L., Goll, R., Clancy, A., Gressnes, T., Valle, P. C., & Broderstad, A. R. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08985-1 · Cited by 21
Manceñido, N., Arribas, B. N., Navarro, G. M., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.06.028 · Cited by 15
Wu, G., Yang, Y., Liu, M., Wang, Y., & Guo, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.655865 · Cited by 13
Applying Telemedicine to Multidisciplinary Pediatric Inflammatory Bowel Disease Care
Michel, H. K., Maltz, R. M., Boyle, B., Donegan, A. M., & Dotson, J. L. (2021) · Children · doi:10.3390/children8050315 · Cited by 11
Rui, M., Fei, Z., Wang, Y., Shi, F., Meng, R., Shang, Y., Ma, A., & Li, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.679258 · Cited by 7
ieta nti-flamatoria or DAIN: A Crohn's disease management strategy tailored for Puerto Ricans
Rojas-Correa, M., Estremera-Rodriguez, L., Yap, Y. R., Díaz-Díaz, L. M., Quintana, M. D. C., Hernandez, L., Madziar, C., Olendzki, B. C., Torres, E. A., & Maldonado‐Contreras, A. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101162 · Cited by 5
Metadata
- Authors
- Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., Battat, R., Bettenworth, D., Bislenghi, G., Brown, S. R., Burisch, J., Casanova, M. J., Czuber-Dochan, W., de Groof, J., El-Hussuna, A., Ellul, P., Fidalgo, C., Fiorino, G., Gisbert, J. P., Sabino, J. G., Hanzel, J., Holubar, S., Iacucci, M., Iqbal, N., Kapizioni, C., Karmiris, K., Kobayashi, T., Kotze, P. G., Luglio, G., Maaser, C., Moran, G., Noor, N., Papamichael, K., Peros, G., Reenaers, C., Sica, G., Sigall-Boneh, R., Vavricka, S. R., Yanai, H., Myrelid, P., Adamina, M., & Raine, T.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-06-15
- Volume
- 18
- Issue
- 10
- Pages
- 1531-1555
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W4399701762
- Cited by
- 388
- References
- 167
- FWCI
- 93.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.